Small molecule therapeutics for immune thrombocytopenia (ITP)
Our groups have been studying the role of human neuraminidase (NEU) enzymes in inflammation. We have developed mechanistic studies which find that NEU1 is critical to the clearance mechanism of platelets in diseases such as idopathic immune thrombocytopenia (ITP). Using genetic knock outs (murine), we confirm that NEU1 activity has a significant effect on platelet clearance. Importantly, using small molecule inhibitors of NEU1 we have established that pharmacological inhibition of the enzyme significantly reduces platelet clearance. We have preclinical data in murine models and are seeking partners to co-develop these compounds for clinical trials.
About University of Alberta
The University of Alberta is a large, comprehensive public research university in Edmonton with multiple campuses and a strong applied research culture. Industry engages through co-located labs and pilot-scale facilities, as well as established co-op and internship programs that place talent with partners year-round. Integration with Alberta’s province-wide hospital system supports clinical research and accelerates translation. Companies also benefit from proximity to regional industry clusters and collaboration hubs on and near campus for joint R&D and prototyping. Supported by NSERC, CIHR, SSHRC, and Canada Foundation for Innovation funding—plus provincial and industry support—the tech transfer office manages IP, licensing, and startup formation with streamlined sponsored-research agreements.
delivered to your inbox.